{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:19:25Z","timestamp":1772090365304,"version":"3.50.1"},"reference-count":147,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.pharma.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T22:43:47Z","timestamp":1445553827000},"page":"93-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Psychopharmacologie de l\u2019anxi\u00e9t\u00e9 et de la d\u00e9pression\u00a0: aspects historiques, traitements actuels et perspectives"],"prefix":"10.1016","volume":"74","author":[{"given":"H.","family":"Javelot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0447.2009.01519.x","article-title":"Prevalence and predictors of recurrence of major depressive disorder in the adult population","volume":"122","author":"Hardeveld","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pharma.2015.09.001_bib0010","series-title":"The age of anxiety: a baroque eclogue","author":"Auden","year":"1947"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1037\/a0022376","article-title":"Recent advances in the treatment of anxiety disorders","volume":"52","author":"Antony","year":"2011","journal-title":"Can Psychol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0020","first-page":"CD008120","article-title":"Second-generation antipsychotics for anxiety disorders","volume":"12","author":"Depping","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pharma.2015.09.001_bib0025","series-title":"Oxford handbook of anxiety and anxiety disorders","article-title":"Anxiety disorders and depression comorbidity","author":"Huppert","year":"2009"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0030","first-page":"3","article-title":"Serotonin neuroscience discoveries usher in a new era of novel drug therapies for psychiatry","volume":"28","author":"Stahl","year":"1992","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"10.1016\/j.pharma.2015.09.001_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/da.20262","article-title":"Role of GABA in anxiety and depression","volume":"24","author":"Kalueff","year":"2007","journal-title":"Depress Anxiety"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0163-7258(89)90006-5","article-title":"Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective","volume":"44","author":"Nutt","year":"1989","journal-title":"Pharmacol Ther"},{"issue":"7407","key":"10.1016\/j.pharma.2015.09.001_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmj.327.7407.158","article-title":"Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease","volume":"327","author":"Shorter","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1476-5381.2011.01362.x","article-title":"The age of anxiety: role of animal models of anxiolytic action in drug discovery","volume":"164","author":"Cryan","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.pharma.2015.09.001_bib0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","article-title":"Anxioselective anxiolytics: on a quest for the Holy Grail","volume":"33","author":"Skolnick","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","article-title":"Hooked on benzodiazepines: GABAA receptor subtypes and addiction","volume":"34","author":"Tan","year":"2011","journal-title":"Trends Neurosci"},{"issue":"7","key":"10.1016\/j.pharma.2015.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v69n0712","article-title":"The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials","volume":"69","author":"Gualtieri","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0070","first-page":"90","article-title":"Side effects of treatment with benzodiazepines","volume":"22","author":"Uzun","year":"2010","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.pharma.2015.09.001_bib0075","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"Billioti de Gage","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2015.09.001_bib0080","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: prospective population based study","volume":"345","author":"Billioti de Gage","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0091-3057(79)90304-6","article-title":"A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety","volume":"11","author":"Lippa","year":"1979","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0090","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"7\u20138","key":"10.1016\/j.pharma.2015.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuropharm.2010.10.020","article-title":"The rise of a new GABA pharmacology","volume":"60","author":"M\u00f6hler","year":"2011","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.108.138859","article-title":"NS11394 [3\u2019-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy","volume":"327","author":"Mirza","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1\u00a0subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat Neurosci"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/FBP.0b013e32835a7c7e","article-title":"Assessment of the effects of NS11394\u00a0and L-838417, a2\/3\u00a0subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function","volume":"23","author":"Hofmann","year":"2012","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pbb.2013.05.004","article-title":"Anxiolytic effects of the GABA(A) receptor partial agonist. L-838,417: impact of age, test context familiarity, and stress","volume":"109","author":"Morales","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"issue":"20","key":"10.1016\/j.pharma.2015.09.001_bib0120","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0125","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1755-5949.2009.00109.x","article-title":"A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder","volume":"16","author":"Czobor","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"1\u20132","key":"10.1016\/j.pharma.2015.09.001_bib0130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejphar.2011.06.054","article-title":"Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73\u00a0in rats trained to discriminate chlordiazepoxide or zolpidem","volume":"668","author":"Vinkers","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0135","first-page":"30","article-title":"Peripheral benzodiazepine receptor: structure and function in health and disease","volume":"61","author":"Papadopoulos","year":"2003","journal-title":"Ann Pharm Fr"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","article-title":"Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function","volume":"27","author":"Papadopoulos","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0145","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2826.2011.02166.x","article-title":"Translocator protein (18kDa) as a target for novel anxiolytics with a favourable side-effect profile","volume":"24","author":"Nothdurfter","year":"2012","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alcohol.2009.02.003","article-title":"The anxiolytic etifoxine protects against convulsant and anxiogenic aspects of the alcohol withdrawal syndrome in mice","volume":"43","author":"Verleye","year":"2009","journal-title":"Alcohol"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/0269881112443746","article-title":"Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?","volume":"27","author":"Owen","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fphar.2013.00166","article-title":"Targeting neurosteroidogenesis as therapy for PTSD","volume":"4","author":"Pinna","year":"2014","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S1092852900027334","article-title":"Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment","volume":"15","author":"Stahl","year":"2010","journal-title":"CNS Spectr"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543784.2011.594039","article-title":"Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited","volume":"20","author":"Prins","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/1520-6394(2000)12:2<111::AID-DA9>3.0.CO;2-3","article-title":"Bupropion-SR in treatment of social phobia","volume":"12","author":"Emmanuel","year":"2000","journal-title":"Depress Anxiety"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0185","first-page":"46","article-title":"A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder","volume":"41","author":"Bystritsky","year":"2008","journal-title":"Psychopharmacol Bull"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.4088\/JCP.v69n0812","article-title":"Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10\u00a0studies","volume":"69","author":"Papakostas","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpsychires.2011.09.003","article-title":"Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Tran","year":"2012","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharma.2015.09.001_bib0200","series-title":"LuAA24530\u00a0shows positive results in major depressive disorder phase II study","author":"Lunbeck","year":"2009"},{"key":"10.1016\/j.pharma.2015.09.001_bib0205","series-title":"Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004\u00a0and Lu AA24530","author":"Lunbeck","year":"2010"},{"key":"10.1016\/j.pharma.2015.09.001_bib0210","series-title":"Antid\u00e9presseurs. Historique","author":"L\u00f4o","year":"2004"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0215","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharma.2015.09.001_bib0220","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","author":"Sanchez","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0225","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0230","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ijcp.12328","article-title":"A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder","volume":"68","author":"Mahableshwarkar","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hup.2371","article-title":"A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5\u00a0and 10mg in acute treatment of adults with generalized anxiety disorder","volume":"29","author":"Mahableshwarkar","year":"2014","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0245","doi-asserted-by":"crossref","first-page":"328","DOI":"10.9734\/INDJ\/2014\/11590","article-title":"Novel and investigational drugs in depression","volume":"2","author":"Shapiro","year":"2014","journal-title":"Int Neuropsychiatr Dis J"},{"key":"10.1016\/j.pharma.2015.09.001_bib0250","first-page":"338","article-title":"Interest of the use of pindolol in the treatment of depression: review","volume":"29","author":"Brousse","year":"2003","journal-title":"Encephale"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbr.2007.12.012","article-title":"5-HT(7) receptors in the modulation of cognitive processes","volume":"195","author":"Cifariello","year":"2008","journal-title":"Behav Brain Res"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0260","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","article-title":"5-HT6\u00a0receptors: a novel target for cognitive enhancement","volume":"108","author":"Mitchell","year":"2005","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0265","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1515\/revneuro-2014-0001","article-title":"Memory formation and memory alterations: 5-HT6\u00a0and 5-HT7\u00a0receptors, novel alternative","volume":"25","author":"Meneses","year":"2014","journal-title":"Rev Neurosci"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0270","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1017\/S1092852913000540","article-title":"Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction","volume":"19","author":"Pehrson","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharma.2015.09.001_bib0275","series-title":"America's biopharmaceutical research companies. Medicines in development for mental health","author":"Pharmaceutical Research, Manufacturers of America (PhRMA)","year":"2014"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0280","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/YIC.0000000000000045","article-title":"Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder","volume":"29","author":"Thase","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2015.09.001_bib0290","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fnbeh.2013.00140","article-title":"Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia","volume":"7","author":"Sumiyoshi","year":"2013","journal-title":"Front Behav Neurosci"},{"issue":"9","key":"10.1016\/j.pharma.2015.09.001_bib0295","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrd4075","article-title":"50years of hurdles and hope in anxiolytic drug discovery","volume":"12","author":"Griebel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.pharma.2015.09.001_bib0300","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/14656566.2014.923403","article-title":"Desvenlafaxine for the treatment of major depressive disorder","volume":"15","author":"Kornstein","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0305","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S1092852900027450","article-title":"Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9\u00a0short-term, double-blind, placebo-controlled trials","volume":"15","author":"Tourian","year":"2010","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharma.2015.09.001_bib0310","series-title":"Questions et r\u00e9ponses sur le retrait de la demande d\u2019autorisation de mise sur le march\u00e9 concernant Ellefore","author":"EMEA","year":"2008"},{"issue":"3\u20134","key":"10.1016\/j.pharma.2015.09.001_bib0315","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0320","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/0269881113494937","article-title":"Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials","volume":"27","author":"Bradley","year":"2013","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0325","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"Eyding","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2015.09.001_bib0330","series-title":"Lilly announces edivoxetine did not meet primary endpoint of phase III clinical studies as add-on therapy for major depressive disorder","author":"Lilly","year":"2013"},{"issue":"7","key":"10.1016\/j.pharma.2015.09.001_bib0335","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"5","key":"10.1016\/j.pharma.2015.09.001_bib0340","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0345","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4155\/fmc.13.158","article-title":"Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?","volume":"6","author":"Zajdel","year":"2014","journal-title":"Future Med Chem"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.pharma.2015.09.001_bib0350","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0355","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharma.2015.09.001_bib0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J Affect Disord"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.pharma.2015.09.001_bib0365","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0165-0327(11)70004-0","article-title":"Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness","volume":"128","author":"Katzman","year":"2011","journal-title":"J Affect Disord"},{"issue":"5\u00a0Suppl.\u00a0B","key":"10.1016\/j.pharma.2015.09.001_bib0370","first-page":"S1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0375","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharma.2015.09.001_bib0380","series-title":"Otsuka and Lundbeck to present new data on brexpipra\/zole in major depression (MDD). 22nd European Psychiatry Association Congress (EPA)","author":"Lundbeck","year":"2014"},{"key":"10.1016\/j.pharma.2015.09.001_bib0385","first-page":"S376","article-title":"Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results: of two pivotal clinical studies","volume":"39","author":"Thase","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14737175.2014.915741","article-title":"The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder","volume":"14","author":"Alamo","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharma.2015.09.001_bib0395","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","author":"Loebel","year":"2014","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pharma.2015.09.001_bib0400","first-page":"1","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4\u00a0pooled, 6-week, placebo-controlled studies","volume":"23","author":"Nasrallah","year":"2014","journal-title":"CNS Spectr"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0405","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12325-013-0006-7","article-title":"Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.pharma.2015.09.001_bib0410","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1586\/14737175.2013.853448","article-title":"Cariprazine, a new, orally active dopamine D2\/3\u00a0receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression","volume":"13","author":"Veselinovi\u0107","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.pharma.2015.09.001_bib0415","unstructured":"Forest et Gedeon Richter, 2014. Donn\u00e9es par communiqu\u00e9s disponibles\u00a0\u2013\u00a021\/03\/2014\u00a0: http:\/\/www.investor.frx.com\/press-release\/r-and-d-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase-ii et 31\/03\/2014\u00a0: http:\/\/www.investor.frx.com\/press-release\/r-and-d-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-positive-phase--0."},{"key":"10.1016\/j.pharma.2015.09.001_bib0420","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/B978-0-444-63425-2.00011-8","article-title":"Dopamine D3\u00a0receptor ligands for drug addiction treatment: update on recent findings","volume":"211","author":"Le Foll","year":"2014","journal-title":"Prog Brain Res"},{"issue":"11","key":"10.1016\/j.pharma.2015.09.001_bib0425","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20years on","volume":"30","author":"Skolnick","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"10.1016\/j.pharma.2015.09.001_bib0430","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1007\/s00213-014-3664-5","article-title":"Ketamine administration in depressive disorders: a systematic review and meta-analysis","volume":"231","author":"Fond","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharma.2015.09.001_bib0435","first-page":"1","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"10","author":"McGirr","year":"2014","journal-title":"Psychol Med"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0440","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(99)00688-6","article-title":"Ketamine stereoselectively inhibits rat dopamine transporter","volume":"274","author":"Nishimura","year":"1999","journal-title":"Neurosci Lett"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0445","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0450","first-page":"56","article-title":"Emerging therapies for treatment resistant depression","volume":"5","author":"Wijesinghe","year":"2014","journal-title":"Ment Health Clin"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0455","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biopsych.2012.10.019","article-title":"A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression","volume":"74","author":"Zarate","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharma.2015.09.001_bib0460","series-title":"Communication affich\u00e9es en poster \u00e0 l\u2019ASCP (American Society of Clinical Pharmacology) Meeting","author":"Astra-Zeneca","year":"2014"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0465","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JCP.0b013e31818a6cea","article-title":"An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder","volume":"28","author":"Preskorn","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0470","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JCP.0b013e31825d70d6","article-title":"A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657\u00a0in patients with treatment-resistant major depressive disorder","volume":"32","author":"Ibrahim","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0475","first-page":"S376","article-title":"Adjunctive GLYX-13\u00a0induces prolonged efficacy in subjects with major depressive disorder (MDD)","volume":"39","author":"Burch","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharma.2015.09.001_bib0480","series-title":"Communiqu\u00e9 de presse. Phoenix, le 10\u00a0d\u00e9cembre 2014. Naurex's GLYX-13\u00a0Demonstrates Robust. Sustained Antidepressant Effects and Excellent Tolerability in Phase 2b Study Phoenix","author":"Naurex","year":"2014"},{"key":"10.1016\/j.pharma.2015.09.001_bib0485","series-title":"Communiqu\u00e9 de presse. Evanston, le 27\u00a0janvier 2015. Naurex's First Orally Active Molecule, NRX-1074. Demonstrates Statistically Significant Improvement in Depression Scores within 24\u00a0Hours in Phase 2\u00a0Study for Major Depressive Disorder","author":"Naurex","year":"2015"},{"key":"10.1016\/j.pharma.2015.09.001_bib0490","series-title":"Communiqu\u00e9 de presse","author":"Roche","year":"2014"},{"key":"10.1016\/j.pharma.2015.09.001_bib0495","series-title":"Communiqu\u00e9 de presse","author":"Roche","year":"2014"},{"issue":"5","key":"10.1016\/j.pharma.2015.09.001_bib0500","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00406-013-0399-y","article-title":"Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders","volume":"263","author":"Hashimoto","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pharma.2015.09.001_bib0505","series-title":"Tracking next-generation neurotherapeutics [No. 208]","author":"NeuroPerspective","year":"2012"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0510","doi-asserted-by":"crossref","first-page":"e00097","DOI":"10.1002\/prp2.97","article-title":"Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.pharma.2015.09.001_bib0515","first-page":"S376","article-title":"The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomized, double-blind, placebo controlled study","volume":"39","author":"Quiroz","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.pharma.2015.09.001_bib0520","doi-asserted-by":"crossref","first-page":"S468","DOI":"10.1016\/S0924-977X(14)70748-5","article-title":"The efficacy and safety of basimglurant as adjunctive therapy in major depression; a randomized, double-blind, placebo controlled study","volume":"24","author":"Quiroz","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0525","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2013.12.019","article-title":"The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders","volume":"723","author":"Pitsikas","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0530","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1517\/13543784.2013.803066","article-title":"Glutamate-based anxiolytic ligands in clinical trials","volume":"22","author":"Wiero\u0144ska","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3928\/02793695-20130513-01","article-title":"Mifepristone as a therapeutic agent in psychiatry","volume":"51","author":"Howland","year":"2013","journal-title":"Psychosoc Nurs Ment Health Serv"},{"key":"10.1016\/j.pharma.2015.09.001_bib0540","unstructured":"Corcept Therapeutics Announces First Quarter 2014\u00a0Financial Results. Menlo Park, CA, 2014\u00a0; disponible via\u00a0: http:\/\/www.corcept.com\/news_events\/view\/pr_1399472860."},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0545","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/nrd3702","article-title":"Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?","volume":"11","author":"Griebel","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0550","first-page":"216","article-title":"NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1\u00a0receptor for the treatment of anxiety and depression","volume":"65","author":"Chen","year":"2005","journal-title":"Drug Development Research Special Issue: New Drug Targets for Depression and Anxiety, Part II: Focus on Peptides"},{"key":"10.1016\/j.pharma.2015.09.001_bib0555","series-title":"A six-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety, and tolerability of GSK561679\u00a0compared to placebo in female subjects, diagnosed with major depressive disorder","author":"GSK","year":"2012"},{"key":"10.1016\/j.pharma.2015.09.001_bib0560","series-title":"Study CRH103390: a 12\u00a0week flexible dose study of GW876008, placebo and active control (paroxetine) in the treatment of social anxiety disorder (SocAD)","author":"GSK","year":"2014"},{"key":"10.1016\/j.pharma.2015.09.001_bib0565","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0079-6123(08)00437-8","article-title":"Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2\u00a0and OT receptors: research tools and potential therapeutic agents","volume":"170","author":"Manning","year":"2008","journal-title":"Prog Brain Res"},{"issue":"11","key":"10.1016\/j.pharma.2015.09.001_bib0570","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4088\/JCP.12m07804","article-title":"The vasopressin V(1b) receptor antagonist SSR 149415\u00a0in the treatment of major depressive and generalized anxiety disorders: results from 4\u00a0randomized, double-blind, placebo-controlled studies","volume":"73","author":"Griebel","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharma.2015.09.001_bib0575","series-title":"Press Release","author":"Sanofi-Aventis","year":"2008"},{"key":"10.1016\/j.pharma.2015.09.001_bib0580","unstructured":"Azevan. http:\/\/www.azevan.com\/pipeline\/default.asp. Information 2014."},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0585","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0166-4328(01)00177-2","article-title":"Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans","volume":"122","author":"Gerra","year":"2001","journal-title":"Behav Brain Res"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1461145712000065","article-title":"Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder","volume":"16","author":"Michelson","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0595","first-page":"1","article-title":"Discontinued anxiolytic drugs (2009\u20132014)","volume":"5","author":"Mandrioli","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.euroneuro.2010.11.012","article-title":"A selective neurokinin-1\u00a0receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial","volume":"21","author":"Mathew","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0605","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0610","series-title":"Press release. Alkermes Announces Positive Results From Study of ALKS 5461\u00a0for Treatment of Major Depressive Disorder. Safety and Tolerability Profile of ALKS 5461\u00a0Confirmed in FORWARD-1\u00a0Study, a Supportive Study in the FORWARD Phase 3\u00a0Pivotal Program","author":"Alkermes","year":"2015"},{"issue":"4","key":"10.1016\/j.pharma.2015.09.001_bib0615","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euroneuro.2013.12.008","article-title":"Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant","volume":"24","author":"Vieta","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharma.2015.09.001_bib0620","first-page":"1","article-title":"Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy","volume":"20","author":"M\u00f6ller","year":"2015","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0625","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000269","article-title":"Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study","volume":"35","author":"Tummala","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.pharma.2015.09.001_bib0630","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4088\/JCP.08m04441","article-title":"Varenicline augmentation in depressed smokers: an 8-week, open-label study","volume":"70","author":"Philip","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0635","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.tips.2010.09.004","article-title":"Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis","volume":"31","author":"Mineur","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharma.2015.09.001_bib0640","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2013.04.027","article-title":"Therapeutic doses of antidepressants are projected not to inhibit human a4b2\u00a0nicotinic acetylcholine receptors","volume":"72","author":"Weber","year":"2013","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pharma.2015.09.001_bib0645","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1017\/S1092852900015418","article-title":"Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent","volume":"12","author":"Stahl","year":"2007","journal-title":"CNS Spectr"},{"issue":"9","key":"10.1016\/j.pharma.2015.09.001_bib0650","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.4088\/JCP.v69n0901","article-title":"L-methylfolate: a vitamin for your monoamines","volume":"69","author":"Stahl","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0655","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1176\/appi.ajp.2012.11071114","article-title":"Lmethylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials","volume":"169","author":"Papakostas","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pharma.2015.09.001_bib0660","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.1094","article-title":"The use of antidepressants in clinical practice: focus on agomelatine","volume":"25","author":"McAllister-Williams","year":"2010","journal-title":"Hum Psychopharmacol"},{"issue":"9","key":"10.1016\/j.pharma.2015.09.001_bib0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3928\/02793695-20110809-01","article-title":"Publication bias and outcome reporting bias: agomelatine as a case example","volume":"49","author":"Howland","year":"2011","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"9","key":"10.1016\/j.pharma.2015.09.001_bib0670","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/11593960-000000000-00000","article-title":"A benefit-risk assessment of agomelatine in the treatment of major depression","volume":"34","author":"Howland","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharma.2015.09.001_bib0675","first-page":"CD008851","article-title":"Agomelatine versus other antidepressive agents for major depression","volume":"12","author":"Guaiana","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0680","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/13543784.2014.911840","article-title":"Agomelatine in treating generalized anxiety disorder","volume":"23","author":"Demyttenaere","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10.1016\/j.pharma.2015.09.001_bib0685","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/14656566.2014.914493","article-title":"An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder","volume":"15","author":"Pizarro","year":"2014","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.pharma.2015.09.001_bib0690","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.pharma.2015.09.001_bib0695","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1176\/ajp.2006.163.12.2186","article-title":"No improvement of posttraumatic stress disorder symptoms with guanfacine treatment","volume":"163","author":"Neylan","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pharma.2015.09.001_bib0700","first-page":"8","article-title":"A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans","volume":"41","author":"Davis","year":"2008","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"10.1016\/j.pharma.2015.09.001_bib0705","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharmthera.2013.10.011","article-title":"The biology of Nociceptin\/Orphanin FQ (N\/OFQ) related to obesity, stress, anxiety, mood, and drug dependence","volume":"141","author":"Witkin","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.pharma.2015.09.001_bib0710","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpsychires.2012.01.027","article-title":"Facing depression with botulinum toxin: a randomized controlled trial","volume":"46","author":"Wollmer","year":"2012","journal-title":"J Psychiatr Res"},{"issue":"7","key":"10.1016\/j.pharma.2015.09.001_bib0715","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/dsu.12175","article-title":"Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines","volume":"39","author":"Hexsel","year":"2013","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.pharma.2015.09.001_bib0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2013.11.006","article-title":"Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial","volume":"52","author":"Finzi","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"8","key":"10.1016\/j.pharma.2015.09.001_bib0725","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4088\/JCP.13m08845","article-title":"Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study","volume":"75","author":"Magid","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharma.2015.09.001_bib0730","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fpsyt.2014.00036","article-title":"Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial","volume":"5","author":"Wollmer","year":"2014","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.pharma.2015.09.001_bib0735","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/npp.2013.342","article-title":"Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?","volume":"39","author":"Belzung","year":"2014","journal-title":"Neuropsychopharmacology"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450915001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450915001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:33:12Z","timestamp":1757719992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450915001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":147,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0003450915001108"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2015.09.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmacologie de l\u2019anxi\u00e9t\u00e9 et de la d\u00e9pression\u00a0: aspects historiques, traitements actuels et perspectives","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}